The percentage of those with early-onset diverticulitis admitted for complicated diverticulitis went from 18.5% to 28.2% from 2005 to 2020.

Physicians with H-1B-sponsored visas accounted for 0.97% of physicians in the United States in fiscal year 2024.

Developers of biosimilars will no longer be required to conduct clinical trials to prove effectiveness for FDA approval.

Primary OS analysis results from STELLAR-303 showed zanzalintinib + atezolizumab improved OS vs regorafenib in metastatic colorectal cancer.

Nearly two-thirds of asymptomatic adults in a US safety-net health care system tested positive for Helicobacter pylori antibodies.